NIAID is establishing a Broad Agency Announcement (BAA) to solicit proposals to address the Institute’s need for improving the immune response of immunocompromised individuals to vaccines and immunotherapies that defend against NIAID Category A, B, or C priority pathogens (listed at http://www2.niaid.nih.gov/biodefense/bandc_priority.htm). The purpose of the BAA is to solicit proposals for research programs that focus on either: 1) the discovery of basic biological mechanisms that cause these immune deficits (Research Area 1); or 2) testing of treatments that are designed to increase the safety and efficacy of such vaccines and immunotherapies in immunocompromised populations (Research Area 2). The ultimate goal of this research program is to protect the human population from potential bioterrorism agents. Therefore, it is expected that research results will provide information that ultimately contributes to the development of new or improved vaccines and/or immunotherapeutic treatments that target the human population, with a focus on immunocompromised individuals. It is anticipated that five (5) to (10) cost-reimbursement, completion type contracts will be awarded, each with a period of five (5) years, beginning approximately September 30, 2005. RFP-NIAID-DMID-BAA-05-11 will be available electronically on or about October 5, 2004, and may be accessed through the NIAID Contract Management Program (CMP) Home Page at http://www.niaid.nih.gov/contract. Any responsible Offeror may submit a proposal which will be considered by the Government. This advertisement does not commit the Government to award a contract. No collect calls will be accepted. Original Point of Contact: Suzanne Dawkins, Contract Specialist, Phone 301-451-3698, Fax 301-480-4675, Email [email protected] - Sharon Kraft, Contracting Officer, Phone 301-496-0195, Fax 301-480-4675, Email [email protected]

Bid Protests Not Available